← AI Health Hub

Allergy & Immunology 2 min read

WellTheory Secures $5 Million for AI-Driven Autoimmune Care Solutions

WellTheory secures $5 million for AI tools in autoimmune care. New features enhance personalized support for patients. πŸ€–πŸ’°

Yusuf Yesil, MD, MIS

WellTheory Secures $5 Million for AI-Driven Autoimmune Care Solutions

WellTheory, a virtual care platform dedicated to individuals with autoimmune diseases, has successfully raised $5 million in funding. This investment will support the launch of two innovative AI tools aimed at enhancing patient care.

Funding Details

The funding round saw participation from:

  • Samsung Next
  • Up2 Fund
  • Opal Ventures
  • Existing investors including OVO Fund, Accel, and BoxGroup
New AI Tools

With the new funding, WellTheory has introduced:

  1. Care Scribe: An AI assistant that aids care teams by transcribing conversations, drafting follow-up notes, and creating personalized care plans for providers to review and customize.
  2. Care Hub: A centralized platform for providers that consolidates member data, lab insights, and session history, streamlining pre- and post-session tasks while enabling automated compliance tracking.
Future Plans

The company intends to utilize the funds to:

  • Expand into employer and health plan markets
  • Accelerate the development of AI technology for both providers and members
CEO Insights

Ellen Rudolph, CEO and co-founder of WellTheory, shared her personal experience with autoimmune disease, highlighting the fragmented and impersonal nature of traditional healthcare. She emphasized that WellTheory aims to bridge this gap by providing personalized care tailored to each member’s needs.

Market Overview

In December, WellTheory launched a women’s health program addressing hormonal conditions such as PCOS, endometriosis, and menopause, which are often linked to autoimmune issues. The company has also established partnerships with employers, including Maven Clinic, to offer nutrition and lifestyle coaching.

WellTheory initially launched with $7.2 million in seed funding, which was led by Accel and included participation from various investors.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment.

Yusuf Yesil, MD, MIS
Yusuf Yesil, MD, MIS

Founder & Medical Doctor at Yesil Science. Clinical Biochemistry Specialist and Health AI researcher focused on clinical decision support, diagnostic AI, and biomedical machine learning.

Follow AI Health Hub